

**Amendments to the Claims**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

Claim 1-3 (canceled)

Claim 4 (previously presented) The antibody Mab 1F1, secreted by the hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the number I-2038.

Claim 5-6 (canceled)

Claim 7 (currently amended) Pharmaceutical composition comprising a therapeutically effective quantity of the monoclonal antibodies according to claim ~~[[1]]~~ **13 or 14**, the said quantity being therapeutically effective for inducing apoptosis in tumor cells.

Claim 8 (currently amended) Hybridoma line capable of secreting monoclonal antibodies according to claim ~~[[1]]~~ **13 or 14**.

Claim 9 (original) Hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the deposit number I-2038.

Claim 10 -12 (canceled)

Claim 13 (currently amended) Monoclonal antibody **directed against the protein of SEQ ID NO:1 and capable of inducing apoptosis in various types of tumor cells, wherein the antibody recognizes according to claim 3, capable of recognizing an epitope between amino acids 22 to 55 of SEQ ID NO:1.**

Claim 14 (currently amended) Monoclonal antibody **directed against the protein of SEQ ID NO:1 and capable of inducing apoptosis in various types of tumor cells,**

**wherein the antibody recognizes** ~~according to claim 13, capable of recognizing an~~  
epitope between amino acids 22-34 of SEQ ID NO:1.